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Abstract
Background: Coronary artery disease (CAD) and cancer remain the leading causes of death
in most developed countries. Elucidating the genetic components that contribute to their
pathogenesis is challenging. In this case-control association study, we examine the association
of single nucleotide polymorphisms (SNPs) in paraoxonase 573 A/G genes, methylene
tetrahydrofolate reductase (MTHFR) 677 C/T and angiotensin-converting enzyme (ACE)
gene insertion/deletion (I/D) polymorphism with CAD independently, as well as synergistically,
in a north Indian population.
Methods and results: Patients with at least 50% stenosis of at least one major coronary
artery were classified as cases. The controls had no myocardial infarction. Polymerase chain
reactions (PCR) followed by restriction fragment length polymorphism (RFLP) analyses were
carried out to determine the SNPs. No significant association of the polymorphisms of the ACE
or MTHFR genes with the risk of CAD was observed. However, the allele frequencies of the 573
A/G polymorphism of the paraoxonase gene differed significantly among cases and controls
before and after controlling for confounding factors. The frequencies of AG vs AA genotypes
and GG+AG vs AA genotypes also differed significantly in the two groups (p = 0.0002). The
interaction of paraoxanase with both MTHFR and ACE independently showed significant
positive associations
Conclusions: The identification of ‘at risk’ individuals by genetic mapping of susceptible
genes for effective control of other host factors will be a very effective and practical approach for
prevention, as well as the development of improved therapy for patients. (Cardiol J 2011; 18, 4:
385–394)
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Introduction
Coronary artery disease (CAD) and cancer re-
main the leading causes of death in most developed
nations. In developing countries like India, an epi-
demiological transition has taken place, and CAD
and other chronic diseases are now coming to the
fore [1, 2]. According to estimates by the World
Health Organization (WHO), nearly seven million
people worldwide die of CAD every year, with most
of these deaths occurring in developing countries
[3]. More than 80% of sudden cardiac deaths are
caused by atherosclerotic CAD, with the remain-
der caused by other diseases [4].
Genetics has traditionally been viewed through
the window of relatively rare single-gene diseases.
It is, however, increasingly apparent that virtually
every medical condition, apart perhaps from sim-
ple trauma, has a genetic component. As is often
evident from a patient’s family history, many com-
mon disorders such as hypertension, heart disease,
asthma, diabetes mellitus, and mental illnesses are
significantly influenced by the genetic background.
These polygenic or multifactorial (complex) disor-
ders involve the contributions of many different
genes, as well as environmental and host factors
that can modify disease risk. A major current chal-
lenge is therefore to elucidate the genetic compo-
nents that contribute to the pathogenesis of com-
plex disorders [5]. Many of our commonest disea-
ses are complex disorders that run in families, but
lack the simple inheritance patterns characteristic
of single gene disorders. Complex diseases have
a low heritability compared to single gene disorders.
Understanding the genetic factors underlying
these complex disorders is therefore challenging
but vital [6]. There has been spectacular success
in identifying the genes responsible for Mendelian
disorders, but the quest for the susceptibility genes
involved in multifactorial diseases such as CAD has
been a struggle [7]. The task of finding a particular
disease-associated gene or genes within this hay-
stack is daunting. Genetic testing for susceptibility
to chronic disease is therefore being increasingly
integrated into the practice of medicine.
Inflammation plays a crucial role in the patho-
genesis of CAD [8]. A number of candidate genes
and loci have recently been identified as being as-
sociated with susceptibility to myocardial infarction
(MI; the most acute form of CAD). Mostly, the gene
products are implicated in the processes of inflam-
mation [9].
In the present case-control association study,
we examined the association of single nucleotide
polymorphisms (SNPs) in three genes: paraoxonase
573 A/G genes, methylene tetrahydrofolate reduc-
tase (MTHFR) 677 C/T, and angiotensin-convert-
ing enzyme (ACE) gene insertion/deletion (I/D)
polymorphism with CAD independently, as well as
synergistically, in a north Indian population. Inde-
pendent studies have been undertaken into the role
and mechanism of the association of the SNPs of
these genes with CAD, but no definitive conclusions
have yet been reached, because of the ethnic diver-
gence of gene polymorphisms. It is therefore im-
portant to examine polymorphisms related to CAD
in low- or high-risk individuals of each ethnic group.
Association studies on the polymorphisms in these
genes have been rare in India. This study was there-
fore carried out in an Indian population to study the
ethnic variations, and their association with CAD.
Methods
Study design
The study sample included 203 sporadic CAD
cases and 212 unrelated healthy control subjects.
The cases were recruited between July 2006 and July
2007 from the patients, belonging primarily to north
India, who had had MI or angina and were being treat-
ed at the Department of Cardiology, GSVM Medical
College, Kanpur, India. All patients (age range 28 to
80 years) were diagnosed using electrocardiography
(ECG) and angiography. Patients who had more than
50% stenosis of at least one major coronary artery,
demonstrated via coronary angiography, were cate-
gorized as CAD patients. The controls were unre-
lated individuals recruited from the Outpatient De-
partment of Cardiology. Their clinical histories were
reviewed in an interview. They had vascular risk
factors such as hypertension, diabetes mellitus,
smoking, and hypercholesterolemia, but no history
or occurrence of MI. Group matching of cases and
controls was done for age and sex.
Arterial hypertension was defined as having
had a previous diagnosis of hypertension or if sys-
tolic or diastolic blood pressure was more than
140 mm Hg or more than 90 mm Hg respectively,
or both, on at least two different occasions.
Subjects were classified as having diabetes
mellitus if their fasting blood glucose level was
more than 126 mg/dL or if they had a history of
being diagnosed with the disease.
 Hypercholesterolemia was defined as having
> 200 mg/dL total cholesterol in the blood.
 Subjects previously or currently smoking to-
bacco were defined as smokers, whereas nonsmo-
kers had no history of smoking.
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The study protocol was approved by the Ethi-
cal Committee for Human Genetics Research of the
Indian Institute of Technology, Kanpur. Informed
written consent was obtained from all individuals
after a full explanation of the study.
Genotype determination
Genomic DNA was extracted from the blood
samples of cases and controls by the ‘salting out’
method. Using the isolated genomic DNA as a tem-
plate, polymerase chain reactions (PCR) were car-
ried out, followed by restriction fragment length
polymorphism (RFLP) analyses to determine the
SNPs. Detailed information on the PCR conditions,
primer sequences, restriction enzymes etc is set
out in Table 1.
Statistical analysis
Data was analyzed using Stats Direct (version
2.5.7) software. Discrete data was reported as fre-
quencies and analyzed using Pearson’s c2 test for
normal distribution. Continuous data was reported
as means with standard deviations and analyzed
using t test. Two-tailed p value was considered, and
values < 0.05 were considered statistically signifi-
cant. Deviation from Hardy-Weinberg equilibrium
proportions was tested for each genetic marker. To
assess the independent association of the genotypes
with CAD, multivariate logistic regression analysis
was performed controlling for the confounding ef-
fects of age, sex, hypertension, smoking and diabe-
tes mellitus. For each odds ratio (OR), 95% confi-
dence intervals (CIs) were calculated. Synergistic
effects of the gene polymorphisms considering
a combination of two or more genes at a time were
assessed using c2 test.
Results
Characteristics of cases and control subjects
Group matching revealed that cases and con-
trols were similar with regards to most characteri-
stics. As expected, patients with CAD were old-
er males and were more frequently diabetic. How-
ever, the controls had higher mean levels of total
cholesterol and low-density lipoproteins (LDL).
More controls had serum cholesterol, serum tri-
glyceride and LDL values higher than the cut-off
values. However, more cases had high-density li-
poprotein (HDL) values lower than the cut-off
values (Table 2).
Genotype frequencies
The genotype frequencies for the ACE, MTHFR
and paraoxonase polymorphisms in the control
groups were in Hardy-Weinberg equilibrium. The D,
T and G allelic frequencies in the control groups
were 53.3%, 13.9% and 22.9% respectively.
Association between ACE I/D
polymorphism and coronary artery disease
The overall distribution of genotypes did not
differ significantly between the cases and controls
(p = 0.21). A lower frequency of the DD genotype
was observed among the cases than in controls
(26.6% vs 34.4%, p = 0.08). Frequencies of the
II genotype were similar in both the groups (30%
vs 27.8%), whereas the D allele in combination with
Table 1. Genotype and allele distribution of
single nucleotide polymorphisms of angiotensin-
-converting enzyme (ACE), methylene tetrahy-
drofolate reductase (MTHFR) and paraoxonase
genes in cases and controls.
ACE I/D
Genotype Cases (n = 203) Controls (n = 212)
DD 54 (26.6%) 73 (34.4%)
ID 88 (43.3%) 80 (37.7%)
II 61 (30.0%) 59 (27.8%)
Allele Cases (n = 406) Controls (n = 424)
D 196 (48.3%) 226 (53.3%)
I 210 (51.7%) 198 (46.7%)
MTHFR 677 C/T
Genotype Cases (n = 203) Controls (n = 212)
TT 9 (4.4%) 3 (1.4%)
CT 50 (24.6%) 53 (25.0%)
CC 144 (70.9%) 156 (%)
Allele Cases (n = 406) Controls (n = 424)
T 68 (16.7%) 59 (13.9%)
C 338 (83.3%) 365 (86.1%)
Paraoxonase 573 A/G
Genotype Cases (n = 203) Controls (n = 212)
GG 12 (5.9%) 10 (4.7%)
AG 108 (53.2%) 77 (36.3%)
AA 83 (40.9%) 125 (59.0%)
Allele Cases (n = 406) Controls (n = 424)
G 132 (32.5%) 97 (22.9%)
A 274 (67.5%) 327 (77.1%)
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I allele occurred somewhat more frequently in cas-
es than in controls (43.3% vs 37.7%, p = 0.24).
Comparison of relative frequencies revealed
that D allelic frequency tended to be enriched in
those without CAD (53.3%) compared to the CAD
patients (48.3%), although the difference did not
achieve significance (p = 0.14).
We also tested a dominant model that com-
pared risk of disease (CAD) with the DD+ID vs
II genotypes; a significant difference was not found
(OR 0.90, p = 0.61). A homozygous comparison (DD
vs II) revealed a trend towards an increased risk of
II (OR 0.72), although it did not achieve significance
(p = 0.18). ID also conferred an increased risk for
CAD, although it did not achieve significance (OR
1.06 for ID vs II, p = 0.79).
Association between MTHFR 677 C/T
polymorphism and coronary artery disease
The overall distribution of genotypes was simi-
lar in the cases and controls (p = 0.18). The fre-
quency of TT genotype was greater in cases than
the controls (4.4% vs 1.4%, p = 0.06). The frequen-
cy of CT genotype was similar in both groups,
whereas CC genotypes were more abundant in con-
trols (73.6% vs 70.9%, p = 0.54). These differenc-
es however did not reach significance level.
The C allelic frequency was found to be en-
riched in the controls, while T was found to be more
prevalent in the cases. A homozygous comparison
(TT vs CC) showed an increased risk of CAD with
TT genotype. The odds of cases having the TT geno-
type, as compared to the CT genotype, were three
times higher than the controls.
Association between paraoxonase 573 A/G
polymorphism and coronary
artery disease
An overall distribution of the genotypes of paraoxo-
nase 573 A/G polymorphism showed significant
differences between cases and controls (p = 0.001).
The frequencies of AG vs AA genotypes and
GG+AG vs AA genotypes also differed significant-
ly in the two groups (p = 0.0002) with an OR of ap-
proximately 2. The comparison of GG vs non GG
genotypes also revealed an odds ratio of greater
than 1, but was not found to be significant. Similar-
ly, a homozygous comparison of the genotypes re-
vealed a greater risk with GG genotype while
AA genotype seemed to be protective.
The G allelic frequency increased in patients
with CAD, whereas A allele was more abundant in
the controls (p = 0.001, OR 1.62, 95% CI 1.18–2.23;
Table 3).
Synergistic effects of gene polymorphisms
on coronary artery disease
To evaluate gene interactions (gene-gene) in
the etiology of CAD, cumulative effects of differ-
ent gene polymorphisms were analyzed by combin-
ing alleles of two or three genes and comparing their
frequencies in the cases and control groups.
Synergistic effect of polymorphisms in two
genes. Interaction of polymorphisms in ACE and
Table 2. Clinical characteristics of the study population.
Determinant Cases (n = 203) Controls (n = 212) P
Age (years) 56.6 ± 12.1 54.5 ± 10.7 0.06
Age range 28–92 20–84
Sex (male/female) 160/43 144/68 0.01
Hypertension 74 (36%) 83 (39%) 0.57
Diabetes 65 (32%) 30 (14%) < 0.0001
Smoking 52 (26%) 40 (19%) 0.09
Serum cholesterol [mg/dL] 174.36 ± 36.17 185.68 ± 41.88 0.003
Serum cholesterol (≥ 200 mg/dL) 44 (22%) 69 (33%) 0.01
Serum triglyceride [mg/dL] 167.64 ± 53.0 170.55 ± 56.11 0.58
Serum triglyceride (> 200 mg/dL) 44 (22%) 69 (33%) 0.01
HDL [mg/dL] 41.56 ± 11.36 41.48 ± 9.26 0.93
HDL < 40 mg/dL 99 (49%) 50 (24%) 0.0000001
LDL [mg/dL] 100.60 ± 31.38 112.32 ± 31.05 0.0001
LDL ≥ 100 mg/dL 97 (48%) 138 (65%) 0.0003
VLDL [mg/dL] 33.95 ± 11.05 34.06 ± 11.94 0.92
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MTHFR genes did not seem to confer an increased
risk, with I+/T+ combination being nearly signifi-
cant (OR 1.57, p = 0.06). The interaction of paraox-
anase with both MTHFR and ACE independently
showed significant positive associations. The pres-
ence of T–/G+ combination was 1.8 times higher
in the cases, indicating a positive association with
CAD. On the other hand, the T–/G+ combination
was found to be protective leading to about a 60%
reduction of risk.
Similarly, evaluation of ACE and paraoxanase syn-
ergism revealed that I+/G+ was significantly more
abundant in the cases. On the other hand, I+/G–
combination and I–/G– combination seemed to be
preventive against CAD. The reduction of risk with
I+/G– and I–/G– combinations were 40% and 90%
respectively. Alone, neither ACE nor MTHFR had
shown any significant association.
We also looked for the synergistic effect of all
three genes combined. We observed that I+/T+/G+
combination of the alleles in either homozygous or
heterozygous forms had two times greater odds
than D+/C+/A+ and non I+/T+/G+ combinations.
It also had about four times greater odds than
I–/T–/G– combination of alleles (Table 4).
After controlling for the confounding effects of
age, sex, hypertension, diabetes and smoking by
multivariate logistic regression analysis, we ob-
served that the 573 A/G polymorphism of the
paraoxonase gene showed significant association
with CAD. The GG+AG was associated with a two
times greater odds of CAD (OR 2.03, 95% CI 1.35–
–3.04) compared to individuals with the AA geno-
type. The TT genotype in MTHFR 677 C/T poly-
morphism also demonstrated approximately four
times greater odds as compared to the CT+CC ge-
notype (Table 5).
Discussion
Natural variations, known as SNPs, in the four
bases from which DNA and genes are composed
lead to most of the genetic differences between in-
dividual people. Association studies at the popula-
tion level help in the fine mapping of alleles. These
studies examine the frequency of specific DNA va-
riants (alleles) in groups of unrelated individuals
with disease and unaffected controls.
Since the commonest and most important
pathological changes in ischemic heart disease are
atherosclerosis and thrombogenesis, and since ge-
netic traits contribute significantly to the risk of
CAD, several studies have investigated whether the
genetic polymorphisms in inflammatory markers
increase the risk of these diseases [9]. The corre-
sponding information in the Indian population was
indequate. We therefore tried to examine in this
case-control association study, whether the gene
variants that are involved in enhancing the risk for
CAD through their contribution to the inflammato-
ry processes and atherosclerosis are also indepen-
dent risk factors for CAD in the study population.
ACE, located in endothelial cells, causes the
conversion of physiologically inactive angiotensin I
to a potent vasoconstrictor angiotensin II. ACE also
inactivates bradykinin, a vasodilator. Both angio-
tensin II and bradykinin play an important role in
cardiovascular regulation through various mecha-
nisms [10–14]. Studies into the association of ACE
I/D polymorphism and MI have shown variable re-
sults. A recent meta-analysis of 15 studies into the
association between the ACE I/D polymorphism and
MI in male dominated populations found a mean OR
of 1.26 for MI of the DD vs ID+II genotypes (95%
CI 1.15–1.39, p = 0.001) [15]. Another meta-analy-
Table 3. Odds ratio of genotype and allele of single
nucleotide polymorphisms of angiotensin-conver-
ting enzyme (ACE), methylene tetrahydrofolate
reductase (MTHFR) and paraoxonase genes.
Genotype OR c2 P 95% CI
comparison
ACE I/D
DD vs non DD 0.69 3.00 0.08 0.44–1.07
II vs non II 0.90 0.25 0.61 0.57–1.40
ID vs non ID 1.26 1.36 0.24 0.84–1.91
ID vs II 1.06 0.07 0.79 0.65–1.75
DD vs II 0.72 1.71 0.19 0.42–1.22
Allele comparisons
D vs I 0.82 2.10 0.14 0.62–1.08
MTHFR 677 C/T
TT vs non TT 3.23 3.36 0.06 0.79–18.78
TT+CT vs CC 1.14 0.36 0.54 0.73–1.80
TT vs CT 3.18 3.01 0.08 0.73–19.11
CT vs CC 1.02 0.01 0.92 0.64–1.64
TT vs CC 3.25 3.37 0.06 0.79–18.96
Allele comparisons
C vs T 1.24 1.29 0.25 0.84–1.85
Paraoxonase 573 A/G
GG vs non GG 1.27 0.29 0.58 0.50–3.25
GG+AG vs AA 2.08 13.55 0.0002 1.38–3.13
AG vs AA 2.11 13.38 0.0002 1.38–3.23
GG vs AA 1.81 1.76 0.18 0.69–4.76
Allele comparisons
G vs A 1.62 9.64 0.001 1.18–2.23
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sis, and several other studies, have suggested
a positive association [16, 17]. However, a number
of other studies have reported negative results [18,
19]. Notable among them is the cohort study by
Lindpaintner et al. [20], which found no association
between the ACE I/D polymorphism and the risk
of CAD. Another meta-analysis reported a mean OR
of 1.26 for MI in DD homozygotes, which was later
found to be due to the confounding effect of publi-
cation bias [15].
We did not observe any significant genotypic
frequency differences for the ACE I/D polymor-
phism between the cases and controls in our study.
The frequency distribution of the genotypes
(DD 26.6%, I/D 43.3%, II 30%) was different com-
pared to most other studies [21–23].
The D allele frequency was found to be lower
in cases than controls, which contradicts observa-
tions made by others [18]. Studies in the Indian
population are too scarce to make comparisons, and
differences in the ethnicity of the population stu-
died may lead to differences in the observed geno-
typic frequencies.
Homocystinuria was first associated with cere-
brovascular disease in 1962 [24, 25]. It has since
been observed that even moderate levels may be
associated with atherosclerosis [26–29]. Genetic
defects of the enzymes or dietary deficiency of
Table 5. Multivariate logistic regression analysis of single nucleotide polymorphisms of angiotensin-
-converting enzyme (ACE), methylene tetrahydrofolate reductase (MTHFR) and paraoxonase genes
(adjusted for age, sex, hypertension, diabetes, and smoking).
Genes and polymorphisms Genotype contrasts OR 95% CI P
ACE I/D DD vs ID+II 0.71 0.46–1.10 0.13
DD+ID vs II 1.04 0.66–1.62 0.87
MTHFR 677 C/T TT vs CT+CC 3.87 0.99–15.18 0.05
TT+CT vs CC 1.09 0.69–1.71 0.70
Paraoxonase 573 A/G GG vs AG+AA 1.37 0.57–3.33 0.48
GG+AG vs AA 2.03 1.35–3.04 0.0007
Table 4. Synergistic effects of combination of single nucleotide polymorphisms of angiotensin-conver-
ting enzyme (ACE), methylene tetrahydrofolate reductase (MTHFR) and paraoxonase genes.
Alleles Cases (n = 203) Controls (n = 212) c2 P OR 95% CI
ACE and MTHFR
I+/T+ 48 (23.6%) 35 (16.5%) 3.30 0.06 1.57 0.94–2.62
I+/T– 101 (49.7%) 104 (49.0%) 0.02 0.88 1.03 0.69–1.54
I–/T+ 11 (5.4%) 21 (9.9%) 2.93 0.08 0.52 0.23–1.17
I–/T– 43 (21.2%) 52 (24.5%) 0.66 0.41 0.83 0.51–1.34
MTHFR and paraoxonase
T+/G+ 34 (16.7%) 26 (12.3%) 1.69 0.19 1.44 0.80–2.59
T+/G– 25 (12.3%) 30 (14.1%) 0.30 0.58 0.85 0.46–1.56
T–/G+ 86 (42.4%) 61 (28.8%) 8.37 0.003 1.82 1.19–2.79
T–/G– 58 (28.6%) 95 (44.8%) 11.75 0.0006 0.42 0.32–0.76
ACE and paraoxonase
I+/G+ 91 (44.8%) 58 (27.3%) 13.75 0.0002 2.16 1.40–3.32
I+/G– 58 (28.6%) 81 (38.2%) 4.32 0.03 0.65 0.42–1.00
I–/G+ 29 (14.3%) 29 (13.7%) 0.03 0.85 1.05 0.58–1.90
I–/G– 25 (12.3%) 44 (20.8%) 59.14 0.00000 0.11 0.06–0.21
ACE, MTHFR and paraoxonase
I+/T+/G+ vs D+/C+/A+ 5.84 0.01 2.24 1.10–4.59
I+/T+/G+ vs I–/T–/G– 9.91 0.001 3.78 1.50–9.63
I+/T+/G+ vs non I+/T+/G+ 6.36 0.01 2.28 1.14–4.61
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B-vitamin cofactors involved in this metabolism re-
sult in elevated homocysteine levels, which has
been associated with an increased risk of coronary
heart disease (CHD). Whether this association is
causal remains uncertain [30, 31].
Observational studies have shown that indivi-
duals with low folate levels or intake have a higher
risk of CHD, and it is possible that these associa-
tions may be independent of homocysteine [32–36].
A common polymorphism exists for the gene that
encodes the MTHFR enzyme, which converts 5,10-
-methylene tetrahydrofolate to 5-methyltetrahydro-
folate, required for the conversion of homocysteine
to methionine.
Individuals who have a C-to-T substitution at
base 677 of the gene have reduced enzyme activity
and higher homocysteine and lower folate levels
than those without this substitution [37–42].
A meta-analysis of 40 studies demonstrated that in-
dividuals with the MTHFR 677 TT genotype have
a 16% higher odds of CHD compared to individuals
with the CC genotype. The results support the hy-
pothesis that impaired folate metabolism, resulting
in high homocysteine concentrations, plays a caus-
al role in the occurrence of CHD. The MTHFR gene
has been cloned and sequenced, and disease-asso-
ciated mutations have been identified [43]. In par-
ticular, a prevalent C-T polymorphism at nucleotide
position 677 results in a conservative Ala to Val
(A223V) replacement. This polymorphism is chara-
cterized by reduced enzyme activity and thermolabil-
ity (tMTHFR) [44] and is likely to be an important
genetic factor contributing to the variation in total
plasma homocysteine (tHcy), which is recognized as
an independent predictor of atherosclerotic disease,
including stroke, MI, and peripheral vascular disease
[45]. Elevated total homocysteine induces oxidative
injury to vascular endothelial cells and impairs the
production of nitric oxide, a strong vascular relaxing
factor, from the endothelium. Hyperhomocysteine-
mia also enhances platelet adhesion to endothelial
cells, promotes growth of vascular smooth muscle
cells, and is associated with higher levels of pro-
thrombotic factors such as thromboglobulin, tissue
plasminogen activator and factor VIIIa.
The association between the MTHFR C677T
polymorphism, the strongest genetic determinant
of moderate hyperhomocysteinemia, which has
been found to be a marker of CAD, has been stu-
died in different settings. The strongest associa-
tions have been reported in European and Asian
studies, whereas a similar trend among North
American studies did not reach statistical signifi-
cance [46]. The T allele in the present study was
not found to be associated with higher CAD risk.
Association of T allele with CAD risk has been re-
ported variably in different studies [46–50].
A recent meta-analysis of 80 studies has given
an estimate of a 14% (95% CI 5–24%) greater risk
of CAD associated with the MTHFR CC genotype
[48]. We however observed a slight predominance
of CC genotypes in the controls. Differences in the
ethnicity of the study population could explain the
differences observed.
Mechanisms underlying the protective effect
of HDL cholesterol (HDL-C) against CHD are not
fully understood. One plausible theory is that the
mechanism is related to the antioxidant properties
of HDL-C, which in turn is determined by its en-
zymes, in particular paraoxonase 1 (PON1) [51–55].
These findings have led to the suggestion that
PON1 activity has a role in susceptibility to athero-
sclerotic disease [52–55]. Recent studies indicate
that PON is one of the enzymes responsible for the
antioxidative and anti-inflammatory properties of
the HDL [56, 57].
In vitro studies indicate that PON can signifi-
cantly reduce lipid peroxide generation during LDL
oxidation, and thus may provide HDL-associated
protection against atherosclerosis. Several case-
-control studies have assessed the association of the
PON1 G192A polymorphism with CHD. A strong
association between a polymorphism in the PON1
gene at position 192 and PON1 activity has been
found [58, 59]. A recent review and meta-analysis
of these studies found a weak overall effect, such
that there was no effect when results were pooled
for studies including 500 or more cases [60].
In the present study, we evaluated the role of
PON1-573 polymorphism and found it to be asso-
ciated with an increased CAD risk before and after
controlling for confounding factors. Other studies
have already analyzed the role of PON1-192 and
PON2-311 polymorphisms in CAD risk, finding
variable results [52, 61–65].
The AA genotype was found to yield protec-
tion against the CAD as compared to the non AA
genotypes as well as the AG genotype. The odds of
having the CAD were higher with the GG genotype
but the association was not found to be significant.
The G allele was associated with a significantly in-
creased risk as compared to the A allele.
In the present study, polymorphism in ACE and
MTHFR genes individually did not show any asso-
ciation with CAD. However, lack of an individual
association for each of these polymorphisms does
not rule them out as risk factors. These alleles
might still confer susceptibility to CAD through
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gene-gene interaction, or gene-environment inter-
action modulated through the involvement of mul-
tiple physiological pathways. This is quite evident
from the associations observed after evaluating for
the synergistic effects of these genes in the present
study. Although our study results must be validat-
ed in larger population-based studies, the synergis-
tic effects observed are quite intriguing.
It is also possible that the examined polymor-
phisms may not be risk factors themselves, but
might be in linkage disequilibrium with another
genetic variant with a definite risk. A comprehen-
sive analysis of all SNPs for each gene with an in-
dependent positive correlation or in combination
with another gene would assist in the identification
of the causal gene variants associated with disease.
The role of the environment and other host
factors in contributing to the susceptibility of mul-
tifactorial diseases in individuals with one or more
predisposing allele is well-known [66]. An environ-
mental vulnerability always persists for genetical-
ly susceptible individuals. Evasion of these factors,
even in the presence of genetic susceptibility, can
therefore postpone, or even prevent, the develop-
ment of the disease. Since CAD, like most other
chronic diseases, is mostly an irreversible process,
prevention is always better than cure.
Identifying ‘at risk’ individuals by genetic map-
ping of susceptible genes for effective control of
other host factors will therefore be a very effective
and practical approach. Apart from their preventive
role, these studies also assist in the development
of improved therapy for patients. Our study sug-
gests the existence of heterogeneity in the genetic
risk factors that could be population-specific, and
calls for rigorous approaches involving a larger
study group for an in-depth analysis.
Limitations of the study
The study is limited by the fact that only CAD
patients who arrived at hospital alive were recruited;
therefore, a possible survival bias should be taken into
account. Nevertheless, this limitation is inherent in
all case-control studies. Another limitation is that
serum values could only be determined for those CAD
patients who survived for at least six months after the
event. On the other hand, the other variables of in-
terest were measured during hospital stay.
Conclusions
The association of paraoxanase with CAD, as
well as the effect of synergism of two and three
genes on CAD, is an interesting observation. Con-
tinued observations in larger, well-defined popula-
tions, with prospective follow-up and control for
other genetic and environmental factors of rele-
vance, would lead to a better understanding of the
genetically determined risk of MI.
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